Home

YCBD

cbdMD, Inc.

NYSEHealthcareDrug Manufacturers - Specialty & Generic

$0.84

-3.45%

2026-05-08

About cbdMD, Inc.

cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States and internationally. The company owns and operates various consumer hemp-based CBD brands. Its cbdMD brand products include oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. It also provides products for dogs and cats, including tinctures, chews, and topicals under the Paw CBD brand name; non-cannabinoid functional ingredients, such as functional mushrooms under the ATRx brand; and hemp-derived solutions under the Herbal Oasis brand. It serves retailers, and health and pet channels through the direct-to-consumer channel, e-commerce platforms, online marketplaces, and wholesale distribution. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. is based in Charlotte, North Carolina.

Key Fundamentals

P/E Ratio

1.40

Forward P/E

-0.94

EPS (TTM)

$0.60

ROE

-43.4%

Revenue Growth (YoY)

-1.9%

Profit Margin

-12.3%

Debt/Equity

6.58

Price/Book

0.94

Beta

2.17

Market Cap

$8.8M

Avg Volume (10D)

1.1M

Recent Breakout Signals

No recent breakout signals detected for YCBD.

Recent Price Range (60 Days)

60D High

$1.27

60D Low

$0.63

Avg Volume

1.5M

Latest Close

$0.84

Get breakout alerts for YCBD

Sign up for Breakout Scanner to receive daily notifications when YCBD triggers breakout signals. Build custom AI screeners and backtest strategies.

Start Free Trial

7-day free trial. No card required.

cbdMD, Inc. (YCBD) is listed on the New York Stock Exchange (NYSE). Breakout Scanner monitors YCBD daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. YCBD operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry. Data is provided for informational purposes only and does not constitute financial advice.